The importance of DNA methylation in prostate cancer development

Journal of Steroid Biochemistry and Molecular Biology

Volumn 166, Issue , 2017, Pages 1-15

  Massie, Charles E ^a   Mills, Ian G ^b,c   Lynch, Andy G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Biomarkers; Epigenetic; Metabolism; Methylation; Mitochondria; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYTOSINE; TUMOR MARKER; AR PROTEIN, HUMAN;

CANCER DIAGNOSIS; CARCINOGENESIS; CELL NUCLEUS; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENETIC ASSOCIATION; HUMAN; METABOLISM; MITOCHONDRION; MOLECULAR CLONING; MOLECULAR STABILITY; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REVIEW; SIGNAL TRANSDUCTION; CPG ISLAND; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; MALE; PROSTATE TUMOR;

BIOMARKERS, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MALE; MITOCHONDRIA; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84964608035     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.04.009     Document Type: Review

References (148)

1. [1] Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N., et al. Exome sequencing identifies recurrent spop, foxa1 and med12 mutations in prostate cancer. Nat. Genet. 44 (2012), 685–689.
2. [2] Kobayashi, M., Ishida, H., Shindo, T., Niwa, S.-I., Kino, M., Kawamura, K., Kamiya, N., Imamoto, T., Suzuki, H., Hirokawa, Y., Shiraishi, T., Tanizawa, T., Nakatani, Y., Ichikawa, T., Molecular analysis of multi-focal prostate cancer by comparative genomic hybridization. Prostate 68 (2008), 1715–1724.
3. [3] Lindberg, J., Mills, I.G., Klevebring, D., Liu, W., Neiman, M., Xu, J., Wikström, P., Wiklund, P., Wiklund, F., Egevad, L., Gr”onberg, H., The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur. Urol. 63 (2013), 702–708.
4. [4] Boyd, L.K., Mao, X., Xue, L., Lin, D., Chaplin, T., Kudahetti, S.C., Stankiewicz, E., Yu, Y., Beltran, L., Shaw, G., Hines, J., Oliver, R.T.D., Berney, D.M., Young, B.D., Lu, Y.-J., High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer 51 (2012), 579–589.
5. [5] Cooper, C.S., Eeles, R., Wedge, D.C., Van Loo, P., Gundem, G., Alexandrov, L.B., Kremeyer, B., Butler, A., Lynch, A.G., Camacho, N., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47 (2015), 367–372.
6. [6] Gundem, G., Van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M., Papaemmanuil, E., Brewer, D.S., Kallio, H.M., Högn”as, G., Annala, M., et al. The evolutionary history of lethal metastatic prostate cancer. Nature, 2015.
7. [7] Ross-Adams, H., Lamb, A., Dunning, M., Halim, S., Lindberg, J., Massie, C., Egevad, L., Russell, R., Ramos-Montoya, A., Vowler, S., et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine 2 (2015), 1133–1144.
8. [8] Tomlins, S.A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005), 644–648.
9. [9] Lee, W.-H., Isaacs, W.B., Bova, G.S., Nelson, W.G., CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 6 (1997), 443–450.
10. [10] Friedlander, T.W., Roy, R., Tomlins, S.A., Ngo, V.T., Kobayashi, Y., Azameera, A., Rubin, M.A., Pienta, K.J., Chinnaiyan, A., Ittmann, M.M., et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 72 (2012), 616–625.
11. [11] Bedford, M.T., Van Helden, P.D., Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 47 (1987), 5274–5276.
12. [12] Lee, W.-H., Morton, R.A., Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S., Hsieh, W.-S., Isaacs, W.B., Nelson, W.G., Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994), 11733–11737.
13. [13] Herman, J.G., Merlo, A., Mao, L., Lapidus, R.G., Issa, J.-P.J., Davidson, N.E., Sidransky, D., Baylin, S.B., Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55 (1995), 4525–4530.
14. [14] Ahmadiyeh, N., Pomerantz, M.M., Grisanzio, C., Herman, P., Jia, L., Almendro, V., He, H.H., Brown, M., Liu, X.S., Davis, M., et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long range interaction with MYC. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 9742–9746.
15. [15] Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C.J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17 (2010), 443–454.
16. [16] Xu, K., Wu, Z.J., Groner, A.C., He, H.H., Cai, C., Lis, R.T., Wu, X., Stack, E.C., Loda, M., Liu, T., et al. EZH2 oncogenic activity in castration resistant prostate cancer cells is polycomb-independent. Science 338 (2012), 1465–1469.
17. [17] Yang, H., Liu, Y., Bai, F., Zhang, J., Ma, S., Liu, J., Xu, Z., Zhu, H., Ling, Z., Ye, D., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32 (2013), 663–669.
18. [18] Lister, R., Pelizzola, M., Dowen, R.H., Hawkins, R.D., Hon, G., Tonti-Filippini, J., Nery, J.R., Lee, L., Ye, Z., Ngo, Q.-M., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462 (2009), 315–322.
19. [19] Garrett-Bakelman, F.E., Sheridan, C.K., Kacmarczyk, T.J., Ishii, J., Betel, D., Alonso, A., Mason, C.E., Figueroa, M.E., Melnick, A.M., Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. J. Vis. Exp., 96, 2015, e52246.
20. [20] Lin, P.-C., Giannopoulou, E.G., Park, K., Mosquera, J.M., Sboner, A., Tewari, A.K., Garraway, L.A., Beltran, H., Rubin, M.A., Elemento, O., Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 15 (2013), 373–383.
21. [21] Sandoval, J., Heyn, H., Moran, S., Serra-Musach, J., Pujana, M.A., Bibikova, M., Esteller, M., Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6 (2011), 692–702.
22. [22] Stott-Miller, M., Zhao, S., Wright, J.L., Kolb, S., Bibikova, M., Klotzle, B., Ostrander, E.A., Fan, J.-B., Feng, Z., Stanford, J.L., Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol. Biomarkers Prev. 23 (2014), 1331–1339.
23. [23] Weber, M., Davies, J.J., Wittig, D., Oakeley, E.J., Haase, M., Lam, W.L., Schuebeler, D., Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37 (2005), 853–862.
24. [24] Luo, J.-H., Ding, Y., Chen, R., Michalopoulos, G., Nelson, J., Tseng, G., Yan, P.Y., Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am. J. Pathol. 182 (2013), 2028–2036.
25. [25] Selker, E.U., Tountas, N.A., Cross, S.H., Margolin, B.S., Murphy, J.G., Bird, A.P., Freitag, M., The methylated component of the Neurospora crassa genome. Nature 422 (2003), 893–897.
26. [26] Aryee, M.J., Liu, W., Engelmann, J.C., Nuhn, P., Gurel, M., Háner, M.C., Esopi, D., Irizarry, R.a., Getzenberg, R.H., Nelson, W.G., Luo, J., Xu, J., Isaacs, W.B., Bova, G.S., Yegnasubramanian, S., DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl. Med., 5, 2013, 169ra10.
27. [27] Brocks, D., Assenov, Y., Minner, S., Bogatyrova, O., Simon, R., Koop, C., Oakes, C., Zucknick, M., Lipka, D.B., Weischenfeldt, J., et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 8 (2014), 798–806.
28. [28] Cancer Genome Atlas Research Network, The molecular taxonomy of primary prostate cancer. Cell 163 (2015), 1011–1025.
29. [29] Rand, A.C., Jain, M., Eizenga, J., Musselman-Brown, A., Olsen, H.E., Akeson, M., Benedict, P., Cytosine variant calling with high-throughput nanopore sequencing. bioRxiv, 2016, 10.1101/047134.
30. [30] Yegnasubramanian, S., Háner, M.C., Zhang, Y., Gurel, B., Cornish, T.C., Wu, Z., Irizarry, R.A., Morgan, J., Hicks, J., DeWeese, T.L., et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68 (2008), 8954–8967.
31. [31] Irizarry, R.A., Ladd-Acosta, C., Carvalho, B., Wu, H., Brandenburg, S.A., Jeddeloh, J.A., Wen, B., Feinberg, A.P., Comprehensive high throughput arrays for relative methylation (CHARM). Genome Res. 18 (2008), 780–790.
32. [32] Landan, G., Cohen, N.M., Mukamel, Z., Bar, A., Molchadsky, A., Brosh, R., Horn-Saban, S., Zalcenstein, D.A., Goldfinger, N., Zundelevich, A., et al. Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues. Nat. Genet. 44 (2012), 1207–1214.
33. [33] Landau, D.A., Clement, K., Ziller, M.J., Boyle, P., Fan, J., Gu, H., Stevenson, K., Sougnez, C., Wang, L., Li, S., et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26 (2014), 813–825.
34. [34] Siegmund, K.D., Marjoram, P., Woo, Y.-J., Tavaré, S., Shibata, D., Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 4828–4833.
35. [35] Hansen, K.D., Timp, W., Bravo, H.C., Sabunciyan, S., Langmead, B., McDonald, O.G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43 (2011), 768–775.
36. [36] Díez-Villanueva, A., Mallona, I., Peinado, M.A., Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenet. Chromatin, 8, 2015, 1.
37. [37] Naeem, H., Wong, N.C., Chatterton, Z., Hong, M.K.H., Pedersen, J.S., Corcoran, N.M., Hovens, C.M., Macintyre, G., Reducing the risk of false discovery enabling identification of biologically significant genomewide methylation status using the HumanMethylation450 array. BMC Genomics, 15, 2014, 51.
38. [38] Paziewska, A., Dabrowska, M., Goryca, K., Antoniewicz, A., Dobruch, J., Mikula, M., Jarosz, D., Zapala, L., Borowka, A., Ostrowski, J., DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. Br. J. Cancer 111 (2014), 781–789.
39. [39] Massie, C.E., Spiteri, I., Ross-Adams, H., Luxton, H., Kay, J., Whitaker, H.C., Dunning, M.J., Lamb, A.D., Ramos-Montoya, A., Brewer, D.S., et al. HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocr.-Relat. Cancer 22 (2015), 131–144.
40. [40] Massie, C.E., Lynch, A., Ramos-Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30 (2011), 2719–2733.
41. [41] Millar, D.S., Ow, K.K., Paul, C.L., Russell, P.J., Molloy, P.L., Clark, S.J., et al. Detailed methylation analysis of the glutathione S-transferase π(GSTP1) gene in prostate cancer. Oncogene 18 (1999), 1313–1324.
42. [42] Santourlidis, S., Florl, A., Ackermann, R., Wirtz, H.-C., Schulz, W.A., High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39 (1999), 166–174.
43. [43] Bastian, P.J., Yegnasubramanian, S., Palapattu, G.S., Rogers, C.G., Lin, X., De Marzo, A.M., Nelson, W.G., Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur. Urol. 46 (2004), 698–708.
44. [44] Jimenez, R.E., Fischer, A.H., Petros, J.A., Amin, M.B., Glutathione S-transferase pi gene methylation: the search for a molecular marker of prostatic adenocarcinoma. Adv. Anat. Pathol. 7 (2000), 382–389.
45. [45] Börno, S.T., Fischer, A., Kerick, M., F”alth, M., Laible, M., Brase, J.C., Kuner, R., Dahl, A., Grimm, C., Sayanjali, B., et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2 (2012), 1024–1035.
46. [46] Kim, J.H., Dhanasekaran, S.M., Prensner, J.R., Cao, X., Robinson, D., Kalyana-Sundaram, S., Huang, C., Shankar, S., Jing, X., Iyer, M., et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res. 21 (2011), 1028–1041.
47. [47] Kron, K., Pethe, V., Briollais, L., Sadikovic, B., Ozcelik, H., Sunderji, A., Venkateswaran, V., Pinthus, J., Fleshner, N., van der Kwast, T., et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS ONE, 4, 2009, e4830.
48. [48] Kron, K., Trudel, D., Pethe, V., Briollais, L., Fleshner, N., van der Kwast, T., Bapat, B., Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin. Cancer Res. 19 (2013), 3450–3461.
49. [49] Mahapatra, S., Klee, E.W., Young, C.Y., Sun, Z., Jimenez, R.E., Klee, G.G., Tindall, D.J., Donkena, K.V., Global methylation profiling for risk prediction of prostate cancer. Clin. Cancer Res. 18 (2012), 2882–2895.
50. [50] Yang, B., Bhusari, S., Kueck, J., Weeratunga, P., Wagner, J., Leverson, G., Huang, W., Jarrard, D.F., Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 15 (2013), 399–408.
51. [51] Yegnasubramanian, S., Kowalski, J., Gonzalgo, M.L., Zahurak, M., Piantadosi, S., Walsh, P.C., Bova, G.S., De Marzo, A.M., Isaacs, W.B., Nelson, W.G., Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64 (2004), 1975–1986.
52. [52] Yu, Y.P., Paranjpe, S., Nelson, J., Finkelstein, S., Ren, B., Kokkinakis, D., Michalopoulos, G., Luo, J.-H., High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 26 (2005), 471–479.
53. [53] Brooks, J.D., Weinstein, M., Lin, X., Sun, Y., Pin, S.S., Bova, G.S., Epstein, J.I., Isaacs, W.B., Nelson, W.G., Cg island methylation changes near the gstp1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 7 (1998), 531–536.
54. [54] Aitchison, A., Warren, A., Neal, D., Rabbitts, P., RASSF1A promoter methylation is frequently detected in both pre-malignant and nonmalignant microdissected prostatic epithelial tissues. Prostate 67 (2007), 638–644.
55. [55] Florl, A., Steinhoff, C., M”uller, M., Seifert, H., Hader, C., Engers, R., Ackermann, R., Schulz, W., Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91 (2004), 985–994.
56. [56] Goessl, C., Krause, H., M”uller, M., Heicappell, R., Schrader, M., Sachsinger, J., Miller, K., Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60 (2000), 5941–5945.
57. [57] Cairns, P., Esteller, M., Herman, J.G., Schoenberg, M., Jeronimo, C., Sanchez-Cespedes, M., Chow, N.-H., Grasso, M., Wu, L., Westra, W.B., et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7 (2001), 2727–2730.
58. [58] Jatkoe, T., Karnes, R., Freedland, S., Wang, Y., Le, A., Baden, J., A urine-based methylation signature for risk stratification within low-risk prostate cancer. Br. J. Cancer 112 (2015), 802–808.
59. [59] Wu, T., Giovannucci, E., Welge, J., Mallick, P., Tang, W., Ho, S., Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br. J. Cancer 105 (2011), 65–73.
60. [60] Haldrup, C., Mundbjerg, K., Vestergaard, E.M., Lamy, P., Wild, P., Schulz, W.A., Arsov, C., Visakorpi, T., Borre, M., Høyer, S., et al. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J. Clin. Oncol. 31 (2013), 3250–3258.
61. [61] Richiardi, L., Fiano, V., Grasso, C., Zugna, D., Delsedime, L., Gillio-Tos, A., Merletti, F., Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS ONE 8 (2013), 1–7.
62. [62] Zelic, R., Fiano, V., Zugna, D., Grasso, C., Delsedime, L., Daniele, L., Galliano, D., Pettersson, A., Gillio-Tos, A., Merletti, F., et al. Global hypomethylation (LINE-1) and gene-specific hypermethylation (GSTP1) on initial negative prostate biopsy as markers of prostate cancer on a rebiopsy. Clin. Cancer Res. 22 (2015), 984–992.
63. [63] Pertega-Gomes, N., Vizcaino, J.R., Felisbino, S., Warren, A.Y., Shaw, G., Kay, J., Whitaker, H., Lynch, A.G., Fryer, L., Neal, D.E., et al. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget 6 (2015), 21675–21684.
64. [64] Sebestyén, E., Zawisza, M., Eyras, E., Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic acids Res. 43 (2015), 1345–1356.
65. [65] Nelson, C.P., La Creis, R.K., Sauvageot, J., Isaacs, W.B., De Marzo, A.M., Groopman, J.D., Nelson, W.G., Kensler, T.W., Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase p1. Cancer Res. 61 (2001), 103–109.
66. [66] Nakayama, M., Bennett, C.J., Hicks, J.L., Epstein, J.I., Platz, E.A., Nelson, W.G., De Marzo, A.M., Hypermethylation of the human glutathione S-transferase-π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163 (2003), 923–933.
67. [67] Mian, O.Y., Khattab, M.H., Hedayati, M., Coulter, J., Abubaker-Sharif, B., Schwaninger, J.M., Veeraswamy, R.K., Brooks, J.D., Hopkins, L., Shinohara, D.B., Cornblatt, B., Nelson, W., Yegnasubramanian, S., DeWeese, T., GSTP1 loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate 76 (2016), 199–206.
68. [68] Kanwal, R., Pandey, M., Bhaskaran, N., MacLennan, G.T., Fu, P., Ponsky, L.E., Gupta, S., Protection against oxidative dna damage and stress in human prostate by glutathione s-transferase p1. Mol. Carcinogen. 53 (2014), 8–18.
69. [69] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.-L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
70. [70] Mosquera, J.M., Beltran, H., Park, K., MacDonald, T.Y., Robinson, B.D., Tagawa, S.T., Perner, S., Bismar, T.A., Erbersdobler, A., Dhir, R., et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15 (2013), 1–10.
71. [71] Tan, H.-L., Sood, A., Rahimi, H.A., Wang, W., Gupta, N., Hicks, J., Mosier, S., Gocke, C.D., Epstein, J.I., Netto, G.J., et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20 (2014), 890–903.
72. [72] Kinoshita, H., Shi, Y., Sandefur, C., Meisner, L.F., Chang, C., Choon, A., Reznikoff, C.R., Bova, G.S., Friedl, A., Jarrard, D.F., Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60 (2000), 3623–3630.
73. [73] Nakayama, T., Watanabe, M., Suzuki, H., Toyota, M., Sekita, N., Hirokawa, Y., Mizokami, A., Ito, H., Yatani, R., Shiraishi, T., Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Investig. 80 (2000), 1789–1796.
74. [74] Jarrard, D.F., Kinoshita, H., Shi, Y., Sandefur, C., Hoff, D., Meisner, L.F., Chang, C., Herman, J.G., Isaacs, W.B., Nassif, N., Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58 (1998), 5310–5314.
75. [75] Gravina, G.L., Marampon, F., Di Staso, M., Bonfili, P., Vitturini, A., Jannini, E.A., Pestell, R.G., Tombolini, V., Festuccia, C., 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 70 (2010), 1166–1178.
76. [76] Gravina, G.L., Festuccia, C., Millimaggi, D., Dolo, V., Tombolini, V., de Vito, M., Vicentini, C., Bologna, M., Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate 68 (2008), 793–801.
77. [77] Zorn, C.S., Wojno, K.J., McCabe, M.T., Kuefer, R., Gschwend, J.E., Day, M.L., 5-aza-2-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin. Cancer Res. 13 (2007), 2136–2143.
78. [78] Li, L.-C., Chui, R., Nakajima, K., Oh, B.R., Au, H.C., Dahiya, R., Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 60 (2000), 702–706.
79. [79] Jones, P.A., Wolkowicz, M.J., Rideout, W.M., Gonzales, F.a., Marziasz, C.M., Coetzee, G.a., Tapscott, S.J., De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl. Acad. Sci. U.S.A. 87 (1990), 6117–6121.
80. [80] Antequera, F., Boyes, J., Bird, A., High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62 (1990), 503–514.
81. [81] Smiraglia, D.J., Rush, L.J., Fr”uhwald, M.C., Dai, Z., Held, W.A., Costello, J.F., Lang, J.C., Eng, C., Li, B., Wright, F.A., Caligiuri, M.A., Plass, C., Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum. Mol. Genet. 10 (2001), 1413–1419.
82. [82] Kawai, J., Hirose, K., Fushiki, S., Comparison of DNA methylation patterns among mouse cell lines by restriction landmark genomic scanning. Mol. Cell. Biol. 14 (1994), 7421–7427.
83. [83] Vertino, P.M., Issa, J.P., Pereira-Smith, O.M., Baylin, S.B., Stabilization of DNA methyltransferase levels and CpG island hypermethylation precede SV40-induced immortalization of human fibroblasts. Cell Growth Differ. 5 (1994), 1395–1402.
84. [84] Tommasi, S., Zheng, A., Weninger, A., Bates, S.E., Li, X.A., Wu, X., Hollstein, M., Besaratinia, A., Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids Res. 41 (2013), 182–195.
85. [85] Degerman, S., Landfors, M., Siwicki, J.K., Revie, J., Borssén, M., Evel”onn, E., Forestier, E., Chrzanowska, K.H., Rydén, P., Keith, W.N., Roos, G., Immortalization of T-cells is accompanied by gradual changes in CpG methylation resulting in a profile resembling a subset of T-cell leukemias. Neoplasia 16 (2014), 606–615.
86. [86] Gordon, K., Clouaire, T., Bao, X.X., Kemp, S.E., Xenophontos, M., de Las Heras, J.I., Stancheva, I., Immortality, but not oncogenic transformation, of primary human cells leads to epigenetic reprogramming of DNA methylation and gene expression. Nucleic Acids Res. 42 (2014), 3529–3541.
87. [87] Varley, K.E., Gertz, J., Bowling, K.M., Parker, S.L., Reddy, T.E., Pauli-Behn, F., Cross, M.K., Williams, B.A., Stamatoyannopoulos, J.A., Crawford, G.E., Absher, D.M., Wold, B.J., Myers, R.M., Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res. 23 (2013), 555–567.
88. [88] Jeter, C.R., Liu, B., Liu, X., Chen, X., Liu, C., Calhoun-Davis, T., Repass, J., Zaehres, H., Shen, J.J., Tang, D.G., NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 30 (2011), 3833–3845.
89. [89] Kregel, S., Szmulewitz, R.Z., Vander Griend, D.J., The pluripotency factor NANOG is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 74 (2014), 1530–1543.
90. [90] Ueki, T., Walter, K.M., Skinner, H., Jáee, E., Hruban, R.H., Goggins, M., Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 21 (2002), 2114–2117.
91. [91] Paz, M.F., Fraga, M.F., Avila, S., Guo, M., Pollan, M., Herman, J.G., Esteller, M., A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63 (2003), 1114–1121.
92. [92] Hennessey, P.T., Ochs, M.F., Mydlarz, W.W., Hsueh, W., Cope, L., Yu, W., Califano, J.A., Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS ONE, 6, 2011, e20584.
93. [93] Nestor, C.E., Ottaviano, R., Reinhardt, D., Cruickshanks, H.A., Mjoseng, H.K., McPherson, R.C., Lentini, A., Thomson, J.P., Dunican, D.S., Pennings, S., Anderton, S.M., Benson, M., Meehan, R.R., Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biol., 16, 2015, 11.
94. [94] Cunningham, D., You, Z., In vitro and in vivo model systems used in prostate cancer research. J. Biol. Methods, 2, 2015, 17.
95. [95] Cock-Rada, A., Weitzman, J.B., The methylation landscape of tumour metastasis. Biol. Cell 105 (2013), 73–90.
96. [96] Reyngold, M., Turcan, S., Giri, D., Kannan, K., Walsh, L.a., Viale, A., Drobnjak, M., Vahdat, L.T., Lee, W., Chan, T.a., Remodeling of the methylation landscape in breast cancer metastasis. PLoS ONE 9 (2014), 1–10.
97. [97] Kim, Y.-J., Yoon, H.-Y., Kim, S.-K., Kim, Y.-W., Kim, E.-J., Kim, I.Y., Kim, W.-J., EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin. Cancer Res. 17 (2011), 4523–4530.
98. [98] Statham, A.L., Robinson, M.D., Song, J.Z., Coolen, M.W., Stirzaker, C., Clark, S.J., Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res. 22 (2012), 1120–1127.
99. [99] Takeshima, H., Wakabayashi, M., Hattori, N., Yamashita, S., Ushijima, T., Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis 36 (2015), 192–201.
100. [100] Taberlay, P.C., Statham, A.L., Kelly, T.K., Clark, S.J., Jones, P.A., Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res. 2014, 1421–1432.
101. [101] Nogales, V., Reinhold, W.C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., Esteller, M., Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget, 2015.
102. [102] Wong, C.P., Hsu, A., Buchanan, A., Palomera-Sanchez, Z., Beaver, L.M., Houseman, E.A., Williams, D.E., Dashwood, R.H., Ho, E., Effects of sulforaphane and 3, 3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLOS ONE, 9, 2014, e86787.
103. [103] Phillip, C.J., Giardina, C.K., Bilir, B., Cutler, D.J., Lai, Y.H., Kucuk, O., Moreno, C.S., Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer, 12, 2012, 145.
104. [104] Shukeir, N., Stefanska, B., Parashar, S., Chik, F., Arakelian, A., Szyf, M., Rabbani, S.A., Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br. J. Pharmacol. 172 (2015), 2769–2781.
105. [105] Pakneshan, P., Xing, R.H., Rabbani, S.A., Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J. 17 (2003), 1081–1088.
106. [106] Costello, L.C., Franklin, R.B., The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol. Cancer, 5, 2006, 17.
107. [107] Serkova, N.J., Gamito, E.J., Jones, R.H., O'Donnell, C., Brown, J.L., Green, S., Sullivan, H., Hedlund, T., Crawford, E.D., The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 68 (2008), 620–628.
108. [108] Giskeødegård, G.F., Bertilsson, H., Selnæs, K.M., Wright, A.J., Bathen, T.F., Viset, T., Halgunset, J., Angelsen, A., Gribbestad, I.S., Tessem, M.-B., Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLOS ONE, 8, 2013, e62375.
109. [109] Clyne, M., Prostate cancer: biopsy citrate concentration could predict prostate cancer growth rate. Nat. Rev. Urol., 9, 2012 123–123.
110. [110] Singh, K.K., Desouki, M.M., Franklin, R.B., Costello, L.C., Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol. Cancer, 5, 2006, 14.
111. [111] Jakobsen, H., Rui, H., Thomassen, Y., Hald, T., Purvis, K., Polyamines and other accessory sex gland secretions in human seminal plasma 8 years after vasectomy. J. Reprod. Fertil. 87 (1989), 39–45.
112. [112] Fjösne, H.E., Strand, H., Sunde, A., Dose-dependent induction of or nithine decarboxylase and S-adenosyl-methionine decarboxylase activity by testosterone in the accessory sex organs of male rats. Prostate 21 (1992), 239–245.
113. [113] Blackshear, P.J., Manzella, J.M., Stumpo, D.J., Wen, L., Huang, J.K., Oyen, O., Young, W.S., High level, cell-specific expression of ornithine decarboxylase transcripts in rat genitourinary tissues. Mol. Endocrinol. 3 (1989), 68–78.
114. [114] Cyriac, J., Haleem, R., Cai, X., Wang, Z., Androgen regulation of spermidine synthase expression in the rat prostate. Prostate 50 (2002), 252–261.
115. [115] van der Graaf, M., Schipper, R.G., Oosterhof, G.O., Schalken, J.A., Verhofstad, A.A., Heerschap, A., Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 10 (2000), 153–159.
116. [116] Smith, R.C., Litwin, M.S., Lu, Y., Zetter, B.R., Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nat. Med. 1 (1995), 1040–1045.
117. [117] Loenen, W.A.M., S-adenosylmethionine: jack of all trades and master of everything?. Biochem. Soc. Trans. 34 (2006), 330–333.
118. [118] Ottaviani, S., Brooke, G.N., O'Hanlon-Brown, C., Waxman, J., Ali, S., Buluwela, L., Characterisation of the androgen regulation of glycine N-methyltransferase in prostate cancer cells. J. Mol. Endocrinol. 51 (2013), 301–312.
119. [119] Khan, A.P., Rajendiran, T.M., Ateeq, B., Asangani, I.A., Athanikar, J.N., Yocum, A.K., Mehra, R., Siddiqui, J., Palapattu, G., Wei, J.T., Michailidis, G., Sreekumar, A., Chinnaiyan, A.M., The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15 (2013), 491–501.
120. [120] Sreekumar, A., Poisson, L.M., Rajendiran, T.M., Khan, A.P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R.J., Li, Y., Nyati, M.K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G.S., Ghosh, D., Pennathur, S., Alexander, D.C., Berger, A., Shuster, J.R., Wei, J.T., Varambally, S., Beecher, C., Chinnaiyan, A.M., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457 (2009), 910–914.
121. [121] Sun, L., Song, L., Wan, Q., Wu, G., Li, X., Wang, Y.Y., Wang, J., Liu, Z., Zhong, X., He, X., Shen, S., Pan, X., Li, A., Wang, Y.Y., Gao, P., Tang, H., Zhang, H., cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res. 25 (2015), 429–444.
122. [122] Tedeschi, P.M., Markert, E.K., Gounder, M., Lin, H., Dvorzhinski, D., Dolfi, S.C., Chan, L.L.-Y., Qiu, J., DiPaola, R.S., Hirshfield, K.M., Boros, L.G., Bertino, J.R., Oltvai, Z.N., Vazquez, A., Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis., 4, 2013, e877.
123. [123] Cuzick, J., Berney, D.M., Fisher, G., Mesher, D., Møller, H., Reid, J.E., Perry, M., Park, J., Younus, A., Gutin, A., Foster, C.S., Scardino, P., Lanchbury, J.S., Stone, S., Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 106 (2012), 1095–1099.
124. [124] Wallace, D.C., Mitochondria and cancer. Nat. Rev. Cancer 12 (2012), 685–698.
125. [125] Larman, T.C., DePalma, S.R., Hadjipanayis, A.G., Protopopov, A., Zhang, J., Gabriel, S.B., Chin, L., Seidman, C.E., Kucherlapati, R., Seidman, J.G., Spectrum of somatic mitochondrial mutations in five cancers. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 14087–14091.
126. [126] Ju, Y.S., Alexandrov, L.B., Gerstung, M., Martincorena, I., Nik-Zainal, S., Ramakrishna, M., Davies, H.R., Papaemmanuil, E., Gundem, G., Shlien, A., et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife, 3, 2014.
127. [127] Arnold, R.S., Sun, C.Q., Richards, J.C., Grigoriev, G., Coleman, I.M., Nelson, P.S., Hsieh, C.-L., Lee, J.K., Xu, Z., Rogatko, A., Osunkoya, A.O., Zayzafoon, M., Chung, L., Petros, J.A., Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate 69 (2009), 1–11.
128. [128] Nass, M.M., Differential methylation of mitochondrial and nuclear DNA in cultured mouse, hamster and virus-transformed hamster cells. In vivo and in vitro methylation. J. Mol. Biol. 80 (1973), 155–175.
129. [129] Vanyushin, B., Kirnos, M., The nucleotide composition and pyrimidine clusters in DNA from beef heart mitochondria. FEBS Lett. 39 (1974), 195–199.
130. [130] Dawid, I.B., 5-Methylcytidylic acid: absence from mitochondrial DNA of frogs and HeLa cells. Science 184 (1974), 80–81.
131. [131] Pollack, Y., Kasir, J., Shemer, R., Metzger, S., Szyf, M., Methylation pattern of mouse mitochondrial DNA. Nucleic Acids Res. 12 (1984), 4811–4824.
132. [132] Cardon, L.R., Burge, C., Clayton, D.A., Karlin, S., Cardont, L.O.N.R., Burget, C., Claytont, D.A., Karlint, S., Pervasive CpG suppression in animal mitochondrial genomes. Proc. Natl. Acad. Sci. U.S.A. 91 (1994), 3799–3803.
133. [133] Shmookler Reis, R.J., Goldstein, S., Mitochondrial DNA in mortal and immortal human cells. Genome number, integrity, and methylation. J. Biol. Chem. 258 (1983), 9078–9085.
134. [134] Groot, G.S., Kroon, A.M., Mitochondrial DNA from various organisms does not contain internally methylated cytosine in -CCGG- sequences. Biochim. Biophys. Acta 564 (1979), 355–357.
135. [135] Agrimi, G., Di Noia, M.A., Marobbio, C.M., Fiermonte, G., Lasorsa, F.M., Palmieri, F., Identification of the human mitochondrial Sadenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distribution. Biochem. J. 379 (2004), 183–190.
136. [136] Shock, L.S., Thakkar, P.V., Peterson, E.J., Moran, R.G., Taylor, S.M., DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 3630–3635.
137. [137] Manev, H., Dzitoyeva, S., Chen, H., Mitochondrial DNA: a blind spot in neuroepigenetics. Biomol. Concepts 3 (2012), 997–1003.
138. [138] Chen, H., Dzitoyeva, S., Manev, H., Effect of valproic acid on mitochondrial epigenetics. Eur. J. Pharmacol. 690 (2012), 51–59.
139. [139] Bellizzi, D., DAquila, P., Giordano, M., Montesanto, A., Passarino, G., Global DNA methylation levels are modulated by mitochondrial DNA variants. Epigenomics 4 (2012), 17–27.
140. [140] Maresca, A., DNA methyltransferase 1 mutations and mitochondrial pathology: is mtDNA methylated?. Front. Genet. 6 (2015), 1–15.
141. [141] Baccarelli, A.A., Byun, H.-M., Platelet mitochondrial DNA methylation: a potential new marker of cardiovascular disease. Clin. Epigenet., 7, 2015, 44.
142. [142] Ghosh, S., Sengupta, S., Scaria, V., Comparative analysis of human mitochondrial methylomes shows distinct patterns of epigenetic regulation in mitochondria. Mitochondrion 18 (2014), 58–62.
143. [143] Takasugi, M., Yagi, S., Hirabayashi, K., Shiota, K., DNA methylation status of nuclear-encoded mitochondrial genes underlies the tissuedependent mitochondrial functions. BMC Genomics, 11, 2010, 481.
144. [144] Chinnery, P.F., Elliott, H.R., Hudson, G., Samuels, D.C., Relton, C.L., Epigenetics, epidemiology and mitochondrial DNA diseases. Int. J. Epidemiol. 41 (2012), 177–187.
145. [145] Kelly, R.D.W., Mahmud, A., McKenzie, M., Trounce, I.A., St John, J.C., Mitochondrial DNA copy number is regulated in a tissue specific manner by DNA methylation of the nuclear-encoded DNA polymerase gamma A. Nucleic Acids Res. 40 (2012), 10124–10138.
146. [146] Lee, W., Johnson, J., Gough, D.J., Donoghue, J., Cagnone, G.L.M., Vaghjiani, V., Brown, K.A., Johns, T.G., St. John, J.C., Mitochondrial DNA copy number is regulated by DNA methylation and demethylation of POLGA in stem and cancer cells and their differentiated progeny. Cell Death Dis., 6, 2015, e1664.
147. [147] Smiraglia, D.J., Kulawiec, M., Bistulfi, G.L., Gupta, S.G., Singh, K.K., A novel role for mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol. Ther. 7 (2008), 1182–1190.
148. [148] Atilano, S.R., Malik, D., Chwa, M., Cáceres-Del-Carpio, J., Nesburn, A.B., Boyer, D.S., Kuppermann, B.D., Jazwinski, S.M., Miceli, M.V., Wallace, D.C., Udar, N., Kenney, M.C., Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes. Hum. Mol. Genet. 24 (2015), 4491–4503.